A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder
El propósito de este estudio es evaluar la eficacia, la seguridad y la tolerabilidad de CYB003 en comparación con un placebo correspondiente como tratamiento adyuvante en participantes con MDD.
- Status
- recruiting
- Phase
- Phase 3
- Institution
- Cybin IRL Limited
- Principal investigator
- Clinical Development
- Start date
- 2024-12-17
- End date
- 2026-09-01
- Registry ID
- NCT06564818
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.